Naim Alkhouri, MD
Gastroenterology · Westlake, OHNPI 1134336662
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (54.1%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. It is spread thinly across 53 manufacturers, the largest accounting for just 17.5%. 2025 is the largest year on record at $606,750, 2.6 times the $230,527 reported in 2019. Among gastroenterology clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,324 payments — averaging $1451.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Madrigal Pharmaceuticals$337K
- Perspectum Diagnostics Ltd$271K
- Ipsen Biopharmaceuticals, Inc$170K
- Novo Nordisk$163K
- Gilead$156K
- Intercept Pharmaceuticals, Inc.$125K
- plus $702K from 47 others
Across 950 payments — averaging $8710.17 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$3.6M
- Gilead$1.7M
- GSK$394K
- Madrigal Pharmaceuticals$301K
- Boehringer Ingelheim$300K
- Genentech, Inc.$291K
- plus $1.8M from 19 others
What the payments were for
- Consulting fees$699,37036%
- Speaking & faculty fees$1,040,16654%
- Travel & lodging$144,9618%
- Food & beverage$37,4822%
- Education$2320%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- REZDIFFRA$306,750
- LiverMultiScan$270,639
- Epclusa$101,965
- Bylvay$92,081
- OCALIVA$89,763
- Mulpleta$80,264
- Mavyret$80,124
- IQIRVO$79,001
- Livdelzi$48,040
- LENVIMA$47,933
- FibroScan$41,817
- Wegovy$40,924
- Velacur$25,000
- Cabometyx$13,674
- DOPTELET$12,348
- XIFAXAN$11,835
- Livmarli$8,718
- ADVIA Centaur XP Analyzer$6,835
- RESMETIROM$5,849
- Kanuma$4,870
How this compares
$1,922,211 in reported general payments places this provider in the 95th percentile of 657 gastroenterology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EpclusaSofosbuvir/Velpatasvir | 36 | $895,932 |
| XifaxanRifaximin | 133 | $433,723 |
| RezdiffraResmetirom | 98 | $381,478 |
| Ursodiol | 193 | $194,619 |
| IqirvoElafibranor | 16 | $184,574 |
| VemlidyTenofovir Alafenamide | 81 | $122,328 |
| OcalivaObeticholic Acid | 12 | $110,171 |
| OzempicSemaglutide | 16 | $15,056 |
| PrografTacrolimus | 13 | $7,474 |
| Sirolimus | 12 | $6,448 |
| Tenofovir Disoproxil Fumarate | 26 | $3,925 |
| Lactulose | 79 | $1,614 |
| Spironolactone | 152 | $1,528 |
| Azathioprine | 29 | $1,057 |
| Tacrolimus | 14 | $903 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadEpclusa, Vemlidy | $155,568 | $1,018,259117 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $12,353 | $433,723133 claims |
| Madrigal PharmaceuticalsRezdiffra | $336,631 | $381,47898 claims |
| Ipsen Biopharmaceuticals, IncIqirvo | $169,633 | $184,57416 claims |
| Intercept Pharmaceuticals, Inc.Ocaliva | $124,886 | $110,17112 claims |
| Novo NordiskOzempic | $163,161 | $15,05616 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 657 gastroenterology providers in Ohio.
Other gastroenterology in Westlake
- Mohamed NaemWestlake$708K
- Mousab TabbaaWestlake$136K
- Rinjal BrahmbhattWestlake$92K
- Kimberly HarrisWestlake$70K
- Michael SpringerWestlake$68K
- Preeti JhawarWestlake$42K
- Pierre GholamCleveland$1.6M
- Anita AfzaliCincinnati$798K
- Kara de FeliceCincinnati$427K
- Tasos ManokasColumbus$411K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.